000			04025nam a22003735i 4500
999			_c76378 _d76378 _x1
001			76378
003			ES-MaUEC
005			20230207040221.0
007			cr nn 008mamaa
008			100301s2006 gw | s |||| 0|eng d
020			_a9783540344476
024	7		_a10.1007/3-540-34447-0 _2doi
040			_bspa _dES-MaUEC
050		4	_aRM301.41 _bC666 2006
100	1		_aConn, Michael. _eeditor literario _936726 _0comprobar BNE20040875774
245	1	0	_aInsights into Receptor Function and New Drug Development Targets _cedited by Michael Conn, Claude Kordon, Yves Christen.
260			_aBerlin, Heidelberg _bSpringer International Publishing _c2006
300			_a1 recurso en línea (XV, 202 p.) :
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aResearch and Perspectives in Endocrine Interactions
505	0		_aMolecular and functional diversity of the TRPC family of ion channels. TRPC channels and their role in ROCE/SOCE -- Functional Rescue of Misfolded Receptor Mutants -- Obesity-related mutations of leptin and melanocortin receptors -- cAMP- and cGMP-dependent control of lipolysis and lipid mobilization in humans: putative targets for fat cell management -- Central Neuropeptide Receptors Involved in Water Balance: Application to Apelin -- Targeting regulators of G protein signaling (RGS proteins) to enhance agonist specificity -- Dimeric GPCRs: what did we learn from the metabotropic glutamate receptors? -- Guiding principles applied in the design of GPCR-selective hypothalamic hormone agonists and antagonists -- Mutations in G proteins and G protein-coupled receptors in human endocrine diseases -- A molecular dissection of the glycoprotein hormone receptors -- Receptor Tyrosine Kinases as Targets for Cancer Therapy Development -- Targets for pituitary tumor therapy -- The endogenous cannabinoid system in the control of food intake and energy balance.
520			_aG-Protein Coupled receptors (GPCRs) and other receptors are significant targets for drug discovery, due to their roles in fundamental physiological processes. Among these roles are: regulation of growth, food intake, reproduction, water balance, sensory perception, blood pressure and heart rate. GPCR-directed drugs account for approximately $40 billion in sales and, of drugs at market, approximately 70% target GPCR function. The availability of combinatorial chemistry coupled with high throughput screening techniques have facilitated discovery of peptidic and non-peptidic ligands of membrane receptors. Mutant receptor models have revealed their role in health and disease and provided insight to new therapeutic approaches, based on control of protein trafficking. Understanding receptor-receptor interactions has provided one mechanism for receptor cross-talk and revealed unexpected interactions. The completion of the human genome has identified a new source of therapeutic targets: "orphan receptors" with unknown functions and yet-to-be discovered ligands. Some orphans have now been identified as ghrelin, nociceptin, apelin, and urocortin. This finding, along with important technologies to develop ligands with desirable characteristics, including peptidomimetics is likely to further accelerate interest in this area.
650		7	_2embne _9671142 _aFarmacoterapia
700	1		_aKordon, Claude _eeditor literario _99123 _0comprobar BNE19942301040
700	1		_aChristen, Yves _eeditor literario _919362 _0comprobar BNE19912857697
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/3-540-34447-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12819967 _b10-10-17 _c01-10-14
942			_2lcc _cLE
945			_aRM301.41 C666 2006 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i1154918x _z06-04-17
988			_aEBSPRINGER
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0